QuidelOrtho (NASDAQ:QDEL) Stock Price Down 3.4% – Should You Sell?

QuidelOrtho Corporation (NASDAQ:QDEL)’s stock price dropped 3.4% on Friday . The stock traded as low as $14.19 and last traded at $14.35. Approximately 111,478 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 1,761,439 shares. The stock had previously closed at $14.85.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on QDEL shares. Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Zacks Research downgraded QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. raised their price objective on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Wednesday, July 1st. Citigroup increased their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of QuidelOrtho in a research report on Monday, June 29th. Three investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $13.62.

QuidelOrtho Trading Up 3.6%

The stock has a market cap of $1.05 billion, a PE ratio of -1.00 and a beta of 0.68. The firm has a 50-day moving average price of $15.81 and a 200-day moving average price of $16.53. The company has a debt-to-equity ratio of 1.43, a quick ratio of 0.76 and a current ratio of 1.39.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.18. The company had revenue of $630.90 million for the quarter, compared to the consensus estimate of $618.72 million. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. QuidelOrtho’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 EPS. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. As a group, equities analysts anticipate that QuidelOrtho Corporation will post 0.75 EPS for the current fiscal year.

Institutional Trading of QuidelOrtho

A number of institutional investors and hedge funds have recently modified their holdings of QDEL. Royal Bank of Canada raised its stake in shares of QuidelOrtho by 1,218.7% in the first quarter. Royal Bank of Canada now owns 80,193 shares of the company’s stock worth $2,803,000 after purchasing an additional 74,112 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in QuidelOrtho by 10.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 228,398 shares of the company’s stock worth $7,987,000 after buying an additional 21,968 shares in the last quarter. Focus Partners Wealth raised its position in QuidelOrtho by 210.9% in the 1st quarter. Focus Partners Wealth now owns 20,454 shares of the company’s stock worth $715,000 after buying an additional 13,876 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in QuidelOrtho during the 2nd quarter valued at about $1,313,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock valued at $93,000 after acquiring an additional 2,309 shares during the last quarter. Institutional investors own 99.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.